Navigation Links
Newly Approved HIV Drug Shows Great Promise
Date:1/30/2008

Pricing Level Should Improve Access

WASHINGTON, Jan. 30 /PRNewswire/ -- The AIDS Institute, a national public policy research, advocacy, and education organization, is encouraged with the FDA's approval of the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) in nearly a decade. TMC125/etravirine was developed by Tibotec Pharmaceuticals, Ltd. and will be marketed in the U.S. by Tibotec Therapeutics as Intelence(R), a division of Ortho Biotech Products, L.P. The company announced introductory pricing for the new NNRTI at $21.80 per day, which is substantially lower than other recently introduced antiretrovirals.

In a Title II Community AIDS National Network release dated January 19, 2008, Dr. Donna Christian-Chistensen, Chair of the Congressional Black Caucus Health Brain Trust stated: "The efficacy that Intelence (TMC125/etravirine) has shown in the DUET studies is impressive. Intelence is an important new HIV medication that, for the first time, re-opens the NNRTI class to patients with NNRTI-resistant virus. We applaud Tibotec for its efforts to make this innovative new medication available and accessible to people living with HIV."

The U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti-HIV medication. This is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced adult patients with HIV resistant to an NNRTI and other antiretroviral (ARV) agents. Intelence, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment- experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other ARV agents. This indication is based on Week 24 analyses from two randomized, double-blind, placebo-controlled trials of Intelence. Both studies were conducted in clinically advanced
'/>"/>

SOURCE The AIDS Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
7. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
8. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
9. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... ANAHEIM, Calif. , July 14, 2014  Mallinckrodt ... (NASDAQ: QCOR ) today announced that the registration ... Exchange Commission ("SEC") by Mallinckrodt plc on May 16, 2014 ... proxy statement of Mallinckrodt and Questcor that also constitutes a ... The registration statement on Form S-4 is available on the ...
(Date:7/14/2014)... BEIJING , July 14, 2014 Sinovac Biotech Ltd. (NASDAQ: ... China , announced today that it will hold its 2014 ... Beijing Time. The meeting will be held at No. 39 Shangdi Xi ... record as of July 9, 2014 will be eligible to vote and ... is to approve the re-election of Weidong Yin , Yuk ...
(Date:7/14/2014)... and LONDON , July 14, 2014 ... IXICO plc (AIM: IXI) jointly announced today the formation ... companies. Dr. Edward Ashton , Ph.D., chief scientific ... have seven members. "The formation of this ... the international commercial and operational alliance we signed with ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7Sinovac Schedules 2014 Annual Meeting of Shareholders 2Sinovac Schedules 2014 Annual Meeting of Shareholders 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9
... by genomics, SAN DIEGO, April 14 ... Therapeutics, Inc. (CTI) (Nasdaq,and MTAX: CTIC), presented data ... patients more likely to respond to treatment with ... for,Cancer Research (AACR) annual meeting. These findings will ...
... April 13 Researchers from the,Barbara Ann ... findings,showing that adding curcumin or resveratrol to ... growth of chemo-resistant colon cancer,cells. The poster ... Cancer Research (AACR) Annual Meeting in San ...
Cached Medicine Technology:New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 2New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 3New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 4New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 5Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
(Date:7/14/2014)... to a new market research report "Power Electronics Market ... (Power IC, Power Module & Power Discrete), Applications, and ... the Power Electronics market is expected to boom in ... at $36.86 Billion and expected to grow at a ... includes an in-depth analysis of the applications and geography. ...
(Date:7/14/2014)... July 14, 2014 This report ... market in Americas. The analysis includes market size ... period and key company share data by revenue ... Brazil and Mexico. It uses data and information ... and in-house analysis. , Scope, ...
(Date:7/14/2014)... (HealthDay News) -- Along with improving vision, cataract surgery ... and other types of dementia, a new study suggests. ... the researchers said. "These preliminary results indicate that ... people with dementia and their loved ones, both visual ... Reserve University and University Hospitals Case Medical Center, in ...
(Date:7/14/2014)... By Kathleen Doheny ... -- Losing a spouse may be linked to multiple health ... new study. For certain seniors, widowhood may even delay ... mild memory problem, losing the spouse was associated with a ... stayed married," said study researcher Dr. Bryan Woodruff. ...
(Date:7/14/2014)... T.E.N., an information technology and security ... nominations will be accepted now through Sept. 12, ... North America Awards. , Awards include the ... executives who have made a positive impact on ... compliance, privacy and information security; and the ISE® ...
Breaking Medicine News(10 mins):Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 2Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 3Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 4Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 5Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3
... cholesterol level in blood.,High level of cholesterol, which is ... can lead to serious health risks. ,// ,Researchers ... examined 199 healthy middle-aged men and women to know ... can increase cholesterol and heighten cardiovascular risk, reports Newswise ...
... of bird flu, even as the government has given approval ... ,The latest outbreaks of the deadly H5N1 strain of ... southwestern province of Yunnan and the northwestern region of Ningxia, ... birds died in Yunnan's Chuxiong district Thursday, and 230 died ...
... is planning expansion of its super-speciality hospital chain with ... Kolkata and Bangalore.// ,"We have embarked on the ... Delhi) which would be ready by 2007-end. We also ... the chain's vice president, told IANS., ,Unlike the ...
... more than 1,200 children, whose organs were removed after death ... average of about ?2,900 in a compensation deal announced recently ... the apex body had fought the cases involving organ-retention ... to a total figure of around ?3.6 million for the ...
... people could be putting their health at risk by ... and other health professionals.// ,The survey of more ... Health Professions Council (HPC), found that about 81% of ... professional were oblivious to whether they were properly qualified ...
... juice has anti-bacterial properties? It has now been found ... compounds that can help preserve dental health by prevention ... University of Rochester Medical Center have been credited with ... acts just similar to a Teflon sheath, commonly used ...
Cached Medicine News:Health News:Wockhardt Group Plans Hospital In Delhi By End-2007 2Health News:Organ Scandals Compensation And The Aftermath 2Health News:Credentials Of Specialists Need To Be Checked 2Health News:Cranberry juice to Prevent Dental Decay 2
... an 125I radioimmunoassay designed for,in ... quantitative,measurement of estradiol in serum, ... in girls,and gynecomastia in men, ... amenorrhea. It is,also intended for ...
... determination of Estradiol (E2) concentration in human serum ... hormone with a phenolic A ring. This ... It is the most potent natural Estrogen, ... smaller amounts by the adrenal cortex, and the ...
... is the most potent, naturally secreted estrogen ... the ovary [1]. In the ovary, estradiol ... estrone, a less potent estrogen derived from ... many body tissues. In men, small amounts ...
... VITROS ECi brings true automation and ... testing. Highly sensitive assays for thyroid, ... bone metabolism testing are currently available, ... The VITROS ECi can simultaneously process ...
Medicine Products: